$70MSeries F, 7 January 2026
Funds a global Phase 3 program for ASP-1929 toward a 2028 FDA BLA submission.
- Amount
- $70M
- Stage
- Series F
- Announced
- 7 January 2026
- Lead
- TaiAx Life Science Fund
- Other investors
- Daiwa Securities, Mitsui Sumitomo Insurance
- Use of funds
- Funds a global Phase 3 program for ASP-1929 toward a 2028 FDA BLA submission.
- Checked
- Announced by the company
- Sources
- Rakuten Medical raises $100M in oversubscribed Series F rakuten-med.com
Rakuten Medical raises $100M in oversubscribed Series F prnewswire.com